US4970076A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Fatty acid composition
Assignee: Efamol Holdings PLC
•
Filing: 1988-12-06
•
Granted: 1990-11-13
•
Expires: 2008-12-06
Abstract
Abstract Composition of a cyclosporin and GLA and DGLA or derivative thereof convertible in the body thereto alone or in a pharmaceutical diluent or carrier.
Inventors
- 👤 David F. Horrobin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 09:42
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/20; A61K38/00; A61K38/04; A61K38/12; A61K38/13; A61P; A61P17/00; A61P29/00; A61P3/00; A61P3/08; A61P37/00; A61P37/02; A61P37/06; A61P43/00
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
73 words
A dosage form of a fatty acid composition alone or in a pharmaceutical diluent or carrier comprising a cyclosporin and a fatty acid selected from the group consisting of GLA, DGLA and a derivative thereof convertible in the body thereto, wherein said fatty acid is in the range of 1 mg to 100 g, and wherein said cyclosporin is in the range of 0.1 ng to 100 mg per ml of said composition.
Claim 2
Dependent Claim
73 words
A dosage form of a fatty acid composition alone or in a pharmaceutical diluent or carrier comprising a cyclosporin and a fatty acid selected from the group consisting of GLA, DGLA and a derivative thereof convertible in the body thereto, wherein said fatty acid is in the range of 1 mg to 100 g, and wherein said cyclosporin is in the range of 0.1 ng to 100 mg per ml of said composition.
Claim 3
Dependent Claim
33 words
A dosage form of a composition according to claim 1 comprising also an n-3 essential fatty acid selected from the 20:5, 22:5 and 22:6 acids or their derivatives convertible in the body thereto.
Claim 4
Independent Claim
106 words
A method of alleviating the renal side effects of administration of cyclosporin comprising administering a dosage form alone or in a pharmaceutical diluent or carrier to a person in need of same (1) a cyclosporin, and (2) a fatty acid selected from the group consisting of GLA, DGLA and a derivative thereof convertible in the body thereto, together or successively to a person suffering from or at risk of such side effects, wherein said fatty acid is in the range of 1 mg to 100 g, and wherein said cyclosporin is in the range of 0.1 ng to 100 mg per ml of said dosage form.
Claim 5
Independent Claim
106 words
A method of alleviating the renal side effects of administration of cyclosporin comprising administering a dosage form alone or in a pharmaceutical diluent or carrier to a person in need of same (1) a cyclosporin, and (2) a fatty acid selected from the group consisting of GLA, DGLA and a derivative thereof convertible in the body thereto, together or successively to a person suffering from or at risk of such side effects, wherein said fatty acid is in the range of 1 mg to 100 g, and wherein said cyclosporin is in the range of 0.1 ng to 100 mg per ml of said dosage form.
Claim 6
Dependent Claim
35 words
A dosage form of a composition according to claim 1 for administration of 50 mg to 10 g of the or each fatty acid and 250 mg to 1.5 g of the cyclosporin, per day.
Claim 7
Dependent Claim
34 words
A dosage form of a composition according to claim 1 comprising 0.1 to 10 mg per ml of the or each fatty acid and 0.1 ng to 1 mg per ml of the cyclosporin.
Claim 8
Dependent Claim
36 words
The method according to claim 3, wherein the GLA or DGLA is administered in an amount of 1 mg to 100 g daily and the amount of cyclosporin administered is 5 mg to 15 g daily.
Claim 9
Dependent Claim
36 words
The method according to claim 3, wherein the GLA or DGLA is administered in an amount of 50 mg to 10 g daily and the amount of cyclosporing administered is 250 mg to 1.5 g daily.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-11-12 | 1994-05-14 | 1994-11-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-11-12 | 1998-05-14 | 1998-11-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-11-12 | 2002-05-14 | 2002-11-13 | $7700.00 | Window Closed / Lapsed |